Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 30, Issue , 2000, Pages S77-S84

  Sulkowski, Mark S ^a   Mast, Eric E ^b   Seeff, Leonard B ^c   Thomas, David L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RIBAVIRIN; ZIDOVUDINE;

CLINICAL TRIAL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIVER TOXICITY; MIXED INFECTION; OPPORTUNISTIC INFECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SECONDARY PREVENTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; HEPATITIS C; HUMAN; INTERFERON-ALPHA; RECURRENCE; RIBAVIRIN;

EID: 0033799253     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313842     Document Type: Review

References (90)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
3. The declining risk of post-transfusion hepatitis C virus infection
4. The risk of transfusion-transmitted viral infections
5. Correlates of hepatitis C virus infections among injection drug users
6. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection
7. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland
8. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam
9. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: An analysis of 309 sex partnerships
10. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
11. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers
12. Lack of evidence for the heterosexual transmission of hepatitis C
13. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: An international, multicenter study
14. Risk factors for hepatitis C virus seropositivity in heterosexual couples
15. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus
16. Mother-to-infant transmission of hepatitis C virus
17. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type l-infected mothers
18. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfectedmothers
19. Hepatitis C in the EuroSIDA cohort of European HIV-infected patients: Prevalence and prognostic value
20. Hepatitis C in hospital employees with needlestick injuries
21. Hepatitis C antibody and chronic liver disease in haemophilia
22. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland
23. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
24. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team
25. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use
26. Clinical outcomes after transfusion-associated hepatitis C
27. Long-term mortality after transfusion-associated non-A, non-B hepatitis
28. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
29. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
30. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States
31. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
32. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population
33. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
34. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
35. The role of liver biopsy in hepatitis C
36. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users
37. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections
38. The progression of HCV-associated liver disease in a cohort of haemophilic patients
39. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study
40. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study
41. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation
42. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
43. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
44. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin
45. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
46. Chronic liver disease in central Harlem: The role of alcohol and viral hepatitis
47. Impact of alcohol on the histological and clinical progression of hepatitis C infection
48. Natural history of liver fibrosis progression in patients with chronic hepatitis C
49. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study
50. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
51. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?
52. Zidovudine-induced hepatotoxicity
53. Severe hepatitis in three AIDS patients treated with indinavir
54. Acute hepatitis in HIV-infected patients during ritonavir treatment
55. Hepatotoxicity after introduction of highly active antiretroviral therapy
56. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-I protease, to treat HIV infection
57. Antituberculosis drug-induced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus
58. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
59. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
60. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
61. Hepatotoxicity associated with antiretroviral therapy in adults with HIV and the role of hepatitis B or C infection
62. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program
63. Syringe exchange and risk of infection with hepatitis B and C viruses
64. Epidemiology of hepatitis C
65. Screeening for hepatitis C in human immunodeficiency virus-infected individuals
66. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
67. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
68. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
69. Hepatitis A among homosexual men and injection drug users: More evidence for vaccination
70. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries
71. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up
72. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men
73. Hepatitis B prevention and human immunodeficiency virus (HIV) infection
74. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV)
75. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C Hepatology
76. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
77. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C
78. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
79. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
80. Recombinant interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
81. Treatment with recombinant α-interferon of chronic hepatitis C in anti-HIV-positive patients
82. Interferon-α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
83. CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C
84. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
85. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
86. Human immunodeficiency virus infection, anemia and survival
87. Ribavirin antagonizes the effect of azidothymidine on HIV replication
88. Effects of drugs on 2', 3'-dideoxy-2', 3'-didehydrothymidine phosphorylation in vitro
89. Ribavirin antagonizes the inhibitory effects of pyrimidine 2', 3'-dideoxynucleosides but enhances inhibitory effects of purine 2', 3'-dideoxy-nucleosides on replication of human immunodeficiency virus in vitro
90. Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus